- Global Pharma News & Resources

GenomOncology announces partnership with Indiana University School of Medicine

GenomOncology announces partnership with Indiana University School of Medicine GenomOncology to provide clinical researchers with real-time clinical trial matching in support of IU's Grand Challenge Precision Health Initiative

PR Newswire

CLEVELAND, Nov. 13, 2018

CLEVELAND, Nov. 13, 2018 /PRNewswire/ -- GenomOncology, LLC (GO) announced today that it was selected by the Indiana University School of Medicine to utilize GO's proprietary match algorithm and GO's extensive Knowledge Management System (KMS) application programming interface (API) suite to provide real-time clinical trial recommendations to clinical researchers for the benefit of IU patients.

GenomOncology's informatics-based service will help IU's clinical research teams discover and evaluate potential clinical trials. GO was chosen after a rigorous technical review and trial matching evaluation with test data.

The GO KMS API suite enables precision health approaches by allowing researchers to aggregate and analyze biomarker-based data within a 'genomics-aware' framework that includes a diverse set of annotations including genes, pathways, drugs, alterations, transcripts, and diseases. GO's KMS clinical trial database contains over 2,900 clinical trials curated by the My Cancer Genome team for comprehensive clinical reporting. The Indiana University School of Medicine is leveraging GO's clinical trial APIs in order to empower researchers to use a patient's clinical and genomic data to find genomically-relevant clinical trials.

"GenomOncology is excited to be working with IU's Precision Health initiative to further IU's goal of increasing cancer clinical trial participation," said Manuel Glynias, CEO of GenomOncology. "We also share their longer term aspirations: to find new treatments for cancer that lead to cures."

The partnership between GO and IU is a part of Indiana University's Grand Challenge Precision Health Initiative (IUPHI) which is conducting clinical trials in triple negative breast cancer, multiple myeloma and pediatric sarcomas.

About IU Precision Health Initiative

The IU Precision Health Initiative was born out of IU's Grand Challenges Program to discover and develop cures for multiple myeloma, triple negative breast cancer and pediatric sarcoma, and to delay progression and ultimately prevent Type 2 diabetes and Alzheimer's disease.

About GenomOncology:
GenomOncology enables the application of genomics in oncology to improve patient care. We have applied our expertise in genomics, technology, and data integration to create solutions for cancer care providers. Our solutions are end-to-end: from the data coming out of a sequencer to the bedside where oncologists make treatment decisions. Our technology streamlines your workflow and creates actionable reports for pathologists. Downstream, we integrate molecular and clinical information to provide oncologists with powerful decision- support tools that enable treatment selection and patient identification for clinical trials- all delivered through a real-time platform. Our solutions also enable "Big Data" analysis of aggregate data to drive research and new insights. Learn more at

Teresa Fletcher, VP of Business Development
Tel: (646) 327-3932

View original content to download multimedia:

SOURCE GenomOncology

Editor Details

Last Updated: 13-Nov-2018